FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600133642> ?p ?o ?g. }

• W2600133642 abstract "e11063 Background: The goal of this study was to compare treatment patterns and outcomes in patients receiving a HER2 directed therapy for the treatment of HER2+ metastatic breast cancer (mBC). Methods: Female mBC patients (with ≥2 claims with ICD9 diagnosis codes for mBC), age ≥18 years receiving treatment with trastuzumab (T) or lapatinib (L) between 1/1/06 and 8/31/11 were identified in the HealthCore Integrated Research Database (HIRD SM ). The earliest mBC claim was defined as index date. Patients with <12 months preindex and ≥6 months postindex continuous eligibility were excluded. Two cohorts were identified: T group received T only; TL group received both L and T (sequentially or together). Treatment duration, metastasis site (mets) at mBC diagnosis, no. of chemotherapy agents, no. of hospitalizations, and total cost of care were assessed in the two groups. Results: Of 1449 patients who received a HER2 directed agent, 1165 were in the T group (mean age 56 yrs) and 284 in the TL group (mean age 54 yrs). T group mets included bone (n=553, 48%), liver (n=336, 29%) and brain (n=283, 24%) mets; TL group had bone mets (n=225, 79%), brain mets (n=167, 59%) and liver mets (n=153, 54%). Mean no. of chemotherapy agents received was lower in T group 3.3 (SD 1.7) compared to TL group 5.8 (SD 2.1) (p=0.0002). The time from 1st mBC diagnosis to treatment with T or L was 117 (SD 217) days in T group and 107 (SD 208) days in TL group. For TL group, time between index date and treatment was 114 (SD 214) days for T and 690 (SD 400) days for L. The mean treatment duration was shorter in T group 417 (SD 366) days compared to TL group 724 (SD 433) days (p<0.0001). TL patients received 579 (SD 402) days of T and 205 (SD 234) days with L. Number of hospitalizations and total cost of care (mean monthly) were 0.1 (SD 0.2) and $12561 (SD $10,975), respectively for T group and 0.1 (SD 0.1) and $13,532 (SD $7,220), respectively for TL group. Conclusions: Mean treatment duration and mean number of chemotherapy agents suggest that the TL group may have received more lines of treatment than the T group. There was no difference in mean monthly costs between the two groups. Medical chart data will be used to confirm treatment patterns and evaluate treatment outcomes in both groups." @default.
• W2600133642 created "2017-04-07" @default.
• W2600133642 creator A5032187510 @default.
• W2600133642 creator A5049635615 @default.
• W2600133642 creator A5060973209 @default.
• W2600133642 creator A5072015843 @default.
• W2600133642 date "2012-05-20" @default.
• W2600133642 modified "2023-09-27" @default.
• W2600133642 title "Treatment patterns and outcomes with HER2-directed therapy for the treatment of HER2-positive metastatic breast cancer." @default.
• W2600133642 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e11063" @default.
• W2600133642 hasPublicationYear "2012" @default.
• W2600133642 type Work @default.
• W2600133642 sameAs 2600133642 @default.
• W2600133642 citedByCount "0" @default.
• W2600133642 crossrefType "journal-article" @default.
• W2600133642 hasAuthorship W2600133642A5032187510 @default.
• W2600133642 hasAuthorship W2600133642A5049635615 @default.
• W2600133642 hasAuthorship W2600133642A5060973209 @default.
• W2600133642 hasAuthorship W2600133642A5072015843 @default.
• W2600133642 hasConcept C121608353 @default.
• W2600133642 hasConcept C126322002 @default.
• W2600133642 hasConcept C143998085 @default.
• W2600133642 hasConcept C2775930923 @default.
• W2600133642 hasConcept C2777329042 @default.
• W2600133642 hasConcept C2779786085 @default.
• W2600133642 hasConcept C530470458 @default.
• W2600133642 hasConcept C71924100 @default.
• W2600133642 hasConceptScore W2600133642C121608353 @default.
• W2600133642 hasConceptScore W2600133642C126322002 @default.
• W2600133642 hasConceptScore W2600133642C143998085 @default.
• W2600133642 hasConceptScore W2600133642C2775930923 @default.
• W2600133642 hasConceptScore W2600133642C2777329042 @default.
• W2600133642 hasConceptScore W2600133642C2779786085 @default.
• W2600133642 hasConceptScore W2600133642C530470458 @default.
• W2600133642 hasConceptScore W2600133642C71924100 @default.
• W2600133642 hasLocation W26001336421 @default.
• W2600133642 hasOpenAccess W2600133642 @default.
• W2600133642 hasPrimaryLocation W26001336421 @default.
• W2600133642 hasRelatedWork W2262516363 @default.
• W2600133642 hasRelatedWork W2327343416 @default.
• W2600133642 hasRelatedWork W2328025331 @default.
• W2600133642 hasRelatedWork W2589789706 @default.
• W2600133642 hasRelatedWork W2594362151 @default.
• W2600133642 hasRelatedWork W2623902247 @default.
• W2600133642 hasRelatedWork W2792435570 @default.
• W2600133642 hasRelatedWork W2900599828 @default.
• W2600133642 hasRelatedWork W2939142118 @default.
• W2600133642 hasRelatedWork W2943379337 @default.
• W2600133642 hasRelatedWork W2943884778 @default.
• W2600133642 hasRelatedWork W2947102908 @default.
• W2600133642 hasRelatedWork W2947582970 @default.
• W2600133642 hasRelatedWork W2980792603 @default.
• W2600133642 hasRelatedWork W2987766669 @default.
• W2600133642 hasRelatedWork W3002073479 @default.
• W2600133642 hasRelatedWork W3094884504 @default.
• W2600133642 hasRelatedWork W3120073818 @default.
• W2600133642 hasRelatedWork W3152999660 @default.
• W2600133642 hasRelatedWork W3092638687 @default.
• W2600133642 isParatext "false" @default.
• W2600133642 isRetracted "false" @default.
• W2600133642 magId "2600133642" @default.
• W2600133642 workType "article" @default.